First Manhattan Co. continued to hold its stake in shares of Novo Nordisk A/S (NYSE:NVO) during the second quarter, according to its most recent disclosure with the SEC. The firm owned 25,762 shares of the company’s stock at the end of the second quarter. First Manhattan Co.’s holdings in Novo Nordisk A/S were worth $1,104,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in the stock. State Street Corp boosted its stake in shares of Novo Nordisk A/S by 64,406.4% in the first quarter. State Street Corp now owns 5,593,351 shares of the company’s stock worth $191,740,000 after buying an additional 5,584,680 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Novo Nordisk A/S by 17.7% in the first quarter. Renaissance Technologies LLC now owns 16,409,200 shares of the company’s stock worth $562,507,000 after buying an additional 2,463,300 shares during the period. Fisher Asset Management LLC boosted its stake in shares of Novo Nordisk A/S by 12.9% in the second quarter. Fisher Asset Management LLC now owns 11,690,997 shares of the company’s stock worth $501,427,000 after buying an additional 1,331,992 shares during the period. Karp Capital Management Corp acquired a new stake in shares of Novo Nordisk A/S during the first quarter worth about $20,651,000. Finally, Sustainable Growth Advisers LP boosted its stake in shares of Novo Nordisk A/S by 17.3% in the first quarter. Sustainable Growth Advisers LP now owns 4,068,896 shares of the company’s stock worth $139,482,000 after buying an additional 598,644 shares during the period. 6.33% of the stock is owned by institutional investors.
Shares of Novo Nordisk A/S (NYSE:NVO) traded down 1.31% on Thursday, reaching $45.47. 1,510,660 shares of the company’s stock traded hands. The stock has a 50-day moving average of $42.90 and a 200 day moving average of $39.06. The firm has a market cap of $112.77 billion, a P/E ratio of 18.60 and a beta of 0.63. Novo Nordisk A/S has a 12-month low of $30.89 and a 12-month high of $47.98.
The business also recently announced an annual dividend, which will be paid on Tuesday, August 29th. Stockholders of record on Monday, August 21st will be paid a dividend of $0.336 per share. This is a positive change from Novo Nordisk A/S’s previous annual dividend of $0.33. This represents a dividend yield of 1.07%. The ex-dividend date of this dividend is Friday, August 18th. Novo Nordisk A/S’s payout ratio is currently 21.33%.
WARNING: “Novo Nordisk A/S (NYSE:NVO) Position Held by First Manhattan Co.” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/08/17/novo-nordisk-as-nysenvo-stake-maintained-by-first-manhattan-co-updated.html.
A number of equities research analysts have recently issued reports on NVO shares. Zacks Investment Research cut shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research note on Wednesday, April 19th. TheStreet raised shares of Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research report on Tuesday, May 2nd. Finally, BidaskClub cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Thursday, June 29th. Four analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $53.00.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
